

To: 5.1.2e [5.1.2e@gmail.com]
 From: 5.1.2e
 Sent: Wed 11/24/2021 7:01:23 AM
 Subject: FW: FOR YOUR INFORMATION: Upcoming ECDC Rapid Risk Assessment - Assessing the current SARS-CoV-2 epidemiological situation
 Received: Wed 11/24/2021 7:01:24 AM

Van: 5.1.2e <5.1.2e@santepubliquefrance.fr>
 Verzonden: dinsdag 23 november 2021 20:03
 Aan: 5.1.5 <5.1.2e@ecdc.europa.eu>; 5.1.2e
 <5.1.2e@ordensklinikum.at>; 5.1.2e <5.1.2e@vzbb.sk>; 5.1.2e
 <5.1.2e@chl.lu>; 5.1.2e <5.1.2e@iss.it>; 5.1.2e <5.1.2e@fhi.no>; 5.1.2e
 <5.1.2e@gov.mt>; 5.1.2e <5.1.2e@rki.de>; 5.1.2e <5.1.2e@landlaeknir.is>; 5.1.2e
 <5.1.2e@mphs.moh.gov.cy>; 5.1.2e <5.1.2e@ssi.dk>; 5.1.2e
 <5.1.2e@phonecoop.coop>; 5.1.2e <5.1.2e@sam.lt>; 5.1.2e <5.1.2e@nijz.si>;
 5.1.2e <5.1.2e@hzjz.hr>; 5.1.2e <5.1.2e@szu.cz>; 5.1.2e <5.1.2e@hpse.ie>; 5.1.2e
 <5.1.2e@insa.min-saude.pt>; 5.1.2e <5.1.2e@spkc.gov.lv>; 5.1.2e
 <5.1.2e@insp.gov.ro>; 5.1.2e <5.1.2e@tcd.ie>; 5.1.2e <5.1.2e@pzph.gov.pl>; 5.1.2e
 <5.1.2e@thl.fi>; 5.1.2e <5.1.2e@mssi.es>; 5.1.2e <5.1.2e@med.uoa.gr>; 5.1.2e
 <5.1.2e@folkhalsomyndigheten.se>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e
 <5.1.2e@sciensano.be>; 5.1.2e <5.1.2e@nnk.gov.hu>
 CC: 5.1.2e <5.1.2e@ecdc.europa.eu>; 5.1.2e <5.1.2e@ecdc.europa.eu>; 5.1.2e
 <5.1.2e@ecdc.europa.eu>; 5.1.2e <5.1.2e@who.int>; 5.1.2e <5.1.2e@yahoo.com>;
 5.1.2e <5.1.2e@nnk.gov.hu>; 5.1.2e <5.1.2e@ages.at>; 5.1.2e <5.1.2e@bkus.lv>;
 5.1.2e <5.1.2e@thl.fi>; 5.1.2e <5.1.2e@mphs.moh.gov.cy>; 5.1.2e
 <5.1.2e@telefonica.net>; 5.1.2e <5.1.2e@hpse.ie>; 5.1.2e <5.1.2e@szu.cz>; 5.1.2e
 <5.1.2e@eody.gov.gr>; 5.1.2e <5.1.2e@inmi.it>; 5.1.2e
 <5.1.2e@nijz.si>; 5.1.2e <5.1.2e@jfmed.uniba.sk>; 5.1.2e <5.1.2e@bkus.lv>;
 <5.1.2e@santerpubliquefrance.fr>; 5.1.2e <5.1.2e@ec.europa.eu>; 5.1.2e
 <5.1.2e@terviseamet.ee>; 5.1.2e <5.1.2e@sciensano.be>; 5.1.2e <5.1.2e@folkhalsomyndigheten.se>;
 5.1.2e <5.1.2e@gov.mt>; 5.1.2e <5.1.2e@hi.lt>; 5.1.2e <5.1.2e@pzph.gov.pl>; 5.1.5
 <5.1.2e@ecdc.europa.eu>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@ssi.dk>;
 5.1.2e <5.1.2e@rki.de>; 5.1.2e <5.1.2e@ec.europa.eu>

Onderwerp: RE: FOR YOUR INFORMATION: Upcoming ECDC Rapid Risk Assessment - Assessing the current SARS-CoV-2 epidemiological situation

Dear ECDC colleagues,

Thank you for sharing this document with us: it is very clear and useful and I only have a few comments/questions (after a fast review considering the deadline), summarised below:

- Page 10 (SARS-CoV-2 variants of concern): you state in the 3rd paragraph regarding AY.4.2 variant that there is "evidence of an increase in transmissibility compared to other Delta lineages". UKHSA stated that there is an increase in the growth rate of AY.4.2 compared to other Delta (as specified later in the paragraph), but they have not yet determined if this increase is linked to an intrinsic increase in the transmissibility of AY.4.2 or to external epidemiological factors. Phrasing it "increase in transmissibility" could lead to the interpretation that AY.4.2 has specific properties leading to an increased transmission, which is misleading.
- In the same chapter, it might be worth mentioning that AY.4.2 is still considered as a Delta (therefore a VOC), and that its classification as VOI underlines the need to specifically follow it and not a decreased risk compared to other Delta, which are VOC.
- Page 19-20 (Model descriptions and assumptions) : last paragraph, it might be worth mentioning how you categorised burden levels as "high risk", "increased risk", "manageable risks" (I did not find such a definition but I've read the document quickly: is it based on the matrix in figure 8 ?)
- Page 23-24 (Booster doses) : would you consider modelling the impact of a booster dose administered 4 or 5 months after vaccination (i.e., before the current 6 months deadline), based on the evidence in this paper

5.1.2e

Immunity after the BNT162b2 Vaccine in Israel. NEJM. <https://www.nejm.org/doi/full/10.1056/NEJMoa2114228>?

Best regards,

5.1.2e



5.1.2e

www.santepubliquefrance.fr

Retrouvez-nous sur



De : 5.1.5 @ecdc.europa.eu>
Envoyé : mardi 23 novembre 2021 10:00
À : 5.1.2e <5.1.2e @ordensklinikum.at>; 5.1.2e <5.1.2e @santerepubliquefrance.fr>; 5.1.2e <5.1.2e @iss.it>; 5.1.2e <5.1.2e @landlaeknir.is>; 5.1.2e <5.1.2e @rki.de>; 5.1.2e <5.1.2e @sam.lt>; 5.1.2e <5.1.2e @szu.cz>; 5.1.2e <5.1.2e @spkc.gov.lv>; 5.1.2e <5.1.2e @pzh.gov.pl>; 5.1.2e <5.1.2e @med.uoa.gr>; 5.1.2e <5.1.2e @rivm.nl>; 5.1.2e <5.1.2e @nnk.gov.hu>
5.1.2e <5.1.2e @ecdc.europa.eu>; 5.1.2e <5.1.2e @vzbb.sk>; 5.1.2e <5.1.2e @fhi.no>; 5.1.2e <5.1.2e @ssi.dk>; 5.1.2e <5.1.2e @nijz.si>; 5.1.2e <5.1.2e @hpsc.ie>; 5.1.2e <5.1.2e @tcd.ie>; 5.1.2e <5.1.2e @gov.mt>; 5.1.2e <5.1.2e @chl.lu>; 5.1.2e <5.1.2e @mphys.moh.gov.cy>; 5.1.2e <5.1.2e @phonecoop.coop>; 5.1.2e <5.1.2e @insa.min-saude.pt>; 5.1.2e <5.1.2e @hzjz.hr>; 5.1.2e <5.1.2e @insp.gov.ro>; 5.1.2e <5.1.2e @thl.fi>; 5.1.2e <5.1.2e @msss.es>; 5.1.2e <5.1.2e @msssi.es>; 5.1.2e <5.1.2e @sciensano.be>; 5.1.2e <5.1.2e @who.int>; 5.1.2e <5.1.2e @ages.at>; 5.1.2e <5.1.2e @ec.europa.eu>; 5.1.2e <5.1.2e @arasnorte.saude.pt>; 5.1.2e <5.1.2e @mphys.moh.gov.cy>; 5.1.2e <5.1.2e @suzu.cz>; 5.1.2e <5.1.2e @inmi.it>; 5.1.2e <5.1.2e @bkus.lv>; 5.1.2e <5.1.2e @jfmed.uniba.sk>; 5.1.2e <5.1.2e @ec.europa.eu>; 5.1.2e <5.1.2e @folkhalsomnydigheten.se>; 5.1.2e <5.1.2e @gmail.com>; 5.1.2e <5.1.2e @hi.lt>; 5.1.2e <5.1.2e @RIVM.NL>; 5.1.2e <5.1.2e @pzh.gov.pl>; 5.1.2e <5.1.2e @rki.de>; 5.1.2e <5.1.2e @ec.europa.eu>

Objet : FOR YOUR INFORMATION: Upcoming ECDC Rapid Risk Assessment - Assessing the current SARS-CoV-2 epidemiological situation

Importance : Haute

Dear Members of the Advisory Forum,

Please find enclosed, for your information, the rapid risk assessment "Assessing the current SARS-CoV-2 epidemiological situation, projections for the end-of-year festive season and strategies for response in the EU/EEA, 17th update", due to be published tomorrow, Wednesday the 24th November, 2021.

We recognise the exceptional approach in our procedure of sharing the Rapid Risk Assessment with you so close to publication, and we thank you for your understanding.

With kind regards,
Executive Office-Governance
On behalf of the ECDC PHE Team

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.